TaiMed Biologics (ROCO:4147) LT-Debt-to-Total-Asset: 0.10 (As of Dec. 2025)

What is TaiMed Biologics LT-Debt-to-Total-Asset?

TaiMed Biologics ROCO:4147 55 LT-Debt-to-Total-Asset is 0.10 as of Dec. 2025. GuruFocus rates ROCO:4147 with a GF Score™ of 55/100 and a GF Value™ of NT$85.93 (Modestly Undervalued).

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. TaiMed Biologics's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.10.

TaiMed Biologics's long-term debt to total assets ratio declined from Dec. 2024 (0.10) to Dec. 2025 (0.10). It may suggest that TaiMed Biologics is progressively becoming less dependent on debt to grow their business.

TaiMed Biologics (ROCO:4147) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

TaiMed Biologics LT-Debt-to-Total-Asset Related Terms

TaiMed Biologics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for TaiMed Biologics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiMed Biologics LT-Debt-to-Total-Asset Chart

TaiMed Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.12

0.13

0.10

TaiMed Biologics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.10	0.10	0.10	0.10	0.10

55GF Score

TaiMed Biologics Inc ROCO:4147

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

TaiMed Biologics LT-Debt-to-Total-Asset Calculation

TaiMed Biologics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	462.999	/	4810.741
	=	0.10

TaiMed Biologics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	462.999	/	4810.741
	=	0.10

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.10 mean?

TaiMed Biologics (ROCO:4147) has a LT-Debt-to-Total-Asset of 0.10 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on TaiMed Biologics and its competitors.

Is TaiMed Biologics' LT-Debt-to-Total-Asset too high?

TaiMed Biologics' current LT-Debt-to-Total-Asset is 0.10. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does TaiMed Biologics' LT-Debt-to-Total-Asset compare to VRTX and REGN?

TaiMed Biologics' LT-Debt-to-Total-Asset of 0.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on TaiMed Biologics and its competitors. TaiMed Biologics's current LT-Debt-to-Total-Asset is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is TaiMed Biologics stock overvalued right now?

Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.93, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.10. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current LT-Debt-to-Total-Asset is 0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.93. GuruFocus considers TaiMed Biologics to be Modestly Undervalued.

Key valuation signals for ROCO:4147:

LT-Debt-to-Total-Asset: 0.10
GF Value™: NT$85.93 vs. price of NT$69.50 (19.1% below fair value)
GF Score™: 55/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TaiMed Biologics Business Description

Industry Healthcare Biotechnology

Comparable Companies ROCO:6535 ROCO:6712 ROCO:6547 TPE:6589 TPE:4169 ROCO:6748 ROCO:4728 TPE:6550 TPE:6541 ROCO:4743 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492

Website https://www.taimedbiologics.com

TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.

55GF Score

Get the complete analysis for ROCO:4147

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$69.50

Price

NT$85.93

GF Value

View ROCO:4147 Analysis

See LT-Debt-to-Total-Asset data for all stocks →